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ABSTRACT
Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular and renal outcomes in patients with type 2
diabetes, including those with diabetic kidney disease. However, the US Food and Drug Administration and European
Medicines Agency warnings about potential adverse effects, such as urosepsis and pyelonephritis, based on post-marketing
case reports, may deter physicians from prescribing these drugs. A recent evaluation of two large US-based databases of
commercial claims failed to find evidence for an increased risk of urinary tract infection (UTI) or severe UTI in type 2
diabetes patients who were prescribed an SGLT2.
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Diabetes mellitus (DM) is a major problem of public health; esti-
mates from the World Health Organization suggest that >15%
of the global adult population may have DM by 2030 [1]. It is the
most common cause of end-stage renal disease [2]. In previous
years, new drug classes for the treatment of type 2 DM have
emerged, including inhibitors of renal sodium–glucose co-trans-
porter-2 (SGLT2); these drugs inhibit glucose reabsorption into
proximal tubular cells, producing mild glycosuria. Thus, apart
from blood glucose reduction, they offer mild but clinically
meaningful decreases in body weight and blood pressure due to
glycosuria-induced calorie loss and natriuresis [3]. Unlike older
antidiabetic agents, recent cardiovascular outcome trials have
shown that SGLT2 inhibitors reduce cardiovascular events and
all-cause mortality in type 2 DM. Furthermore, secondary analy-
ses of the above trials, as well as a recent trial with primary re-
nal outcome, clearly suggest that these agents can largely
retard the progression of renal disease in type 2 DM [4–6].
Current knowledge suggests that SGLT2 inhibitors reduce glo-
merular hyperfiltration, intraglomerular pressure and urinary
albumin excretion through reversal of the vasodilation of the af-
ferent arteriole, that is through a mechanism different to that of
renin–angiotensin system blockers, offering a unique opportu-
nity for nephroprotection [4, 6]. Based on the above, recent
guidelines and consensus statements recommend the preferred
use of SGLT2 inhibitors as a second step (after metformin) in
type 2 DM patients with atherosclerotic cardiovascular disease,
chronic kidney disease (CKD) or heart failure [4, 7]. Furthermore,
these agents are currently being explored as nephroprotective
and cardioprotective agents in non-diabetic individuals [8].
In major trials with SGLT2 inhibitors, the overall rates of
adverse effects were significantly lower in the active drug
groups than in the placebo groups [9–11], indicating a
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generally safe profile. However, the mode of action of these
agents is theoretically expected to be associated with adverse
reactions related to glycosuria [4]. Urinary frequency and vol-
ume depletion–associated symptoms have been more com-
mon in the SGLT2 inhibitor group in only one [10] of the three
major cardiovascular trials [9–11]. Previous reports on in-
creased incidences of acute kidney injury (AKI) with these
agents were also not confirmed in clinical trials, as AKI epi-
sodes were less frequent in the SGLT2 inhibitor groups [9–11].
Thus genitourinary tract infections appeared to be the most
common complication undermining their use. Among them,
genital mycotic infections, although generally mild in sever-
ity and resolving with topical treatment, were indeed from 4-
to 9-fold, more common in the SGLT2 inhibitor groups than in
the placebo groups in major trials [9–11]. In contrast to the
solid information on genital infections, early data on the inci-
dence of urinary tract infections (UTIs) during SGLT2 treat-
ment were not consistent, generating confusion among
treating physicians.
The presence of DM itself increases UTI risk by 1.5- to 4-fold;
development of UTIs in individuals with diabetes is a major
problem, as it further increases the risk of complications, hospi-
talizations and death and elevates economic burden [12, 13]. In
2015, the US Food and Drug Administration (FDA) revised labels
for all SGLT2 inhibitors to add a warning about increased risk of
severe UTIs [14]. This warning followed 19 cases of urosepsis
and pyelonephritis reported to the FDA, which by itself was of
limited scientific value due to the absence of comparator and
denominator. The European Medicines Agency considers UTIs
(including pyelonephritis and urosepsis) as common adverse
reactions of these drugs, citing post-marketing cases of pyelo-
nephritis and urosepsis for empagliflozin and canagliflozin [15–
17]. Such warnings, however, may induce fear of UTIs among
treating physicians and cause the underuse of SGLT2 inhibitors,
despite their undisputed benefit on cardiovascular outcomes
and mortality.
In contrast to the above, in major outcome studies, the risk
of UTIs with SGLT2 inhibitors was similar to that with placebo.
In Empagliflozin Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients–Removing Excess Glucose (EMPA-
REG OUTCOME), the overall occurrence of UTIs was 18.0 and
18.1% and that of complicated UTI (defined as pyelonephritis,
urosepsis or a serious adverse event consistent with UTI) was
1.7 and 1.8% in the empagliflozin and placebo groups, respec-
tively [9]. In the CANagliflozin cardioVascular Assessment
Study (CANVAS) programme, the relevant incidence with cana-
gliflozin and placebo was 40 versus 37 UTI events per 1000
patient-years (P¼ 0.38) [10], while in the Multicenter Trial to
Evaluate the Effect of Dapagliflozin on the Incidence of
Cardiovascular Events (DECLARE–TIMI) trial, UTIs were reported
in 1.5 and 1.6% of dapagliflozin- or placebo-treated patients
(P¼ 0.54) [11]. These results are strengthened by a recent meta-
analysis including data from 86 randomized clinical trials with
50 880 patients [18]. Therein there was no significant difference
in the risk of UTIs when SGLT2 inhibitors were compared with
placebo {relative risk [RR] 1.03 [95% confidence interval (CI) 0.96–
1.11]} or active drugs [RR 1.08 (95% CI 0.93–1.25)]. In drug-specific
analyses, empagliflozin [RR 0.99 (95% CI 0.91–1.08)] and canagli-
flozin [RR 1.10 (95% CI 0.90–1.33)] were not associated with in-
creased risk of UTI versus placebo, but dapagliflozin was [RR
1.23 (95% CI 1.03–1.46)]; the latter was a dose-dependent associa-
tion evident with dapagliflozin 10 mg but not with dapagliflozin
5 mg daily. In comparisons against active drugs, no individual
SGLT2 inhibitor demonstrated an increased risk of UTI.
As the findings of clinical trials with regards to safety out-
comes are not always directly generalizable to everyday clinical
practice, in a recent observational study, Dave et al. [19] aimed to
answer this question. They used data from two US databases of
patients with employer-based insurance. Within each database
they created through 1:1 propensity score matching one cohort of
adult type 2 DM patients that were initiating SGLT2 inhibitors
versus dipeptidyl peptidase-4 (DPP-4) inhibitors (Cohort 1) or
SGLT2 inhibitors versus glucagon-like peptide-1 (GLP-1) receptor
agonists (Cohort 2). New use was defined as no use of the rele-
vant drugs for a 180-day window before study entry. Cohort entry
was restricted to between March 2013 and September 2015.
Patients with evidence of nursing home or hospice care, gesta-
tional DM, type 1 DM, cancer, human immunodeficiency virus or
renal insufficiency (CKD, acute renal failure or end-stage renal
disease), as well as those with a high risk of UTI (hydronephrosis,
vesicoureteral reflux, spinal cord injuries or catheter use) and
those with a history of UTI were excluded from the analysis.
With propensity score matching performing adjustment for >90
baseline characteristics, Cohort 1 included 123 752 patients and
Cohort 2 included 111 978 patients. The primary outcome (severe
UTI event, defined as a hospitalization for primary UTI, hospitali-
zation for sepsis with UTI or pyelonephritis) occurred in 61 indi-
viduals newly starting SGLT2 inhibitors (1.76 events/1000 person-
years) and 57 individuals starting DPP-4 inhibitors (1.77 events/
1000 person-years) in Cohort 1 [hazard ratio (HR) 0.98, (95% CI
0.68–1.41)]. In Cohort 2, the relevant rates were 2.15 versus 2.96
events/1000 person-years for those starting SGLT2 inhibitors ver-
sus GLP-1 agonists [HR 0.72 (95% CI 0.53–0.99)]. The individual
components of the primary outcome showed similar trends, with
a significant difference for hospitalization for sepsis with UTI
favouring SGLT2 inhibitors in Cohort 2 [HR 0.54 (95% CI 0.36–
0.82)]. SGLT2 inhibitors were also not associated with an in-
creased risk for treated outpatient UTIs [Cohort 1: HR 0.96 (95% CI
0.89–1.04); Cohort 2: HR 0.91 (95% CI 0.84–0.99)] [19].
These important results suggest that SGLT2 inhibitors are
not associated with an increased risk of severe or outpatient
UTIs compared with DDP-4 inhibitors or GLP-1 agonists in ev-
eryday practice. Among the study’s strengths, one can list the
large samples that provided an adequate number of events, es-
pecially with regards to the rare outcome of severe UTI, which is
a clinically relevant endpoint. A thorough process of propensity
score matching enabled the formation of balanced groups for a
wide set of factors. Furthermore, the authors performed sensi-
tivity and subgroup analyses, indicating the robustness of their
findings [19]. However, some limitations are also present.
The authors excluded patients at high risk of UTI or with a
previous history of UTI; such patients are not uncommon in the
diabetic population. They also excluded patients with CKD, a fact
that introduces a considerable gap in the literature, as SGLT2
inhibitors may have much wider use in such patients, following
recent evidence of nephroprotection [4–6]. The authors had no in-
formation to perform adjustments for DM duration and severity
(indicated by haemoglobin A1c), which are clinically relevant fac-
tors. Furthermore, even with the best methodology, the presence
of residual confounding cannot be excluded, as in all retrospec-
tive cohort studies. Confounding by indication is obviously possi-
ble [20], that is doctors could have intentionally not prescribed
SGLT2 inhibitors in patients they consider at risk for a UTI or in
patients with a previous history of UTIs (which can be present
and not reported in a claims database, as patients with mild UTIs
are often self-treated). To minimize such an effect, the authors
performed subgroup analyses of risk factors for UTI (use of ste-
roids, antibiotics, anti-rheumatic drugs and history of mycotic
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infections), but this is restricted to 180 days before cohort entry
and the lifetime UTI history is not considered. Findings suggest-
ing that indication biases are present is the unexpected lower in-
cidence of severe UTIs, UTI hospitalizations and outpatient UTIs
with SGLT2 inhibitors versus GLP-1 receptor agonists. For this to
have biological plausibility, background data suggesting that GLP-
1 receptor agonists predispose to UTIs or SGLT2 inhibitors protect
against them had to exist, but in both cases, they are obviously
absent.
Overall, data from major outcome trials clearly suggest that
SGLT2 inhibitors are not associated with an increased risk of
UTIs [9–11]. The recent analysis from Dave et al. [19] added a set
of real-world data pointing in the same direction. Observational
studies including patients with a UTI history or specific popula-
tions (CKD, the elderly) are pieces of evidence that would ad-
vance our knowledge in the field. However, already existing
data on the association of SGLT2 inhibitors with UTIs are largely
reassuring and should enable more extended use of these drugs
for the benefit of our patients.
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